Fate Therapeutics Financial Statements (FATE)
|
|
|
|
Report date
|
|
|
02.03.2020 |
24.02.2021 |
28.02.2022 |
28.02.2023 |
26.02.2024 |
|
12.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
10.7 |
31.4 |
55.8 |
96.3 |
63.5 |
|
13.4 |
|
Operating Income, bln rub |
|
|
-100.7 |
-128.1 |
-217.0 |
-308.4 |
-190.5 |
|
-196.6 |
|
EBITDA, bln rub |
? |
|
-94.2 |
-125.0 |
-211.1 |
-294.6 |
-172.2 |
|
-178.2 |
|
Net profit, bln rub |
? |
|
-97.7 |
-170.3 |
-206.3 |
-255.1 |
-160.9 |
|
-178.2 |
|
|
OCF, bln rub |
? |
|
-83.2 |
-39.2 |
-162.9 |
-248.2 |
-132.3 |
|
-131.7 |
|
CAPEX, bln rub |
? |
|
7.40 |
4.93 |
50.7 |
35.6 |
6.15 |
|
0.813 |
|
FCF, bln rub |
? |
|
-90.6 |
-44.2 |
-213.6 |
-283.8 |
-138.4 |
|
-132.5 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
111.4 |
159.5 |
272.8 |
404.7 |
254.0 |
|
200.3 |
|
Cost of production, bln rub |
|
|
87.8 |
125.6 |
5.85 |
13.8 |
161.7 |
|
44.3 |
|
R&D, bln rub |
|
|
87.8 |
125.6 |
215.5 |
320.5 |
172.6 |
|
123.5 |
|
Interest expenses, bln rub |
|
|
1.75 |
0.000 |
0.000 |
5.84 |
0.000 |
|
9.71 |
|
|
Assets, bln rub |
|
|
302.3 |
622.5 |
921.5 |
705.6 |
506.2 |
|
495.0 |
|
Net Assets, bln rub |
? |
|
244.8 |
384.4 |
678.8 |
483.9 |
368.4 |
|
362.3 |
|
Debt, bln rub |
|
|
26.9 |
97.3 |
114.8 |
109.3 |
103.5 |
|
99.0 |
|
Cash, bln rub |
|
|
221.4 |
482.9 |
615.9 |
436.2 |
315.2 |
|
296.9 |
|
Net debt, bln rub |
|
|
-194.5 |
-385.6 |
-501.1 |
-326.9 |
-211.6 |
|
-197.9 |
|
|
Ordinary share price, rub |
|
|
19.6 |
90.9 |
58.5 |
10.1 |
3.74 |
|
2.20 |
|
Number of ordinary shares, mln |
|
|
68.2 |
82.4 |
94.7 |
96.8 |
98.4 |
|
117.8 |
|
|
Market cap, bln rub |
|
|
1 334 |
7 491 |
5 544 |
977 |
368 |
|
259 |
|
EV, bln rub |
? |
|
1 140 |
7 106 |
5 043 |
650 |
156 |
|
61 |
|
Book value, bln rub |
|
|
245 |
384 |
679 |
484 |
368 |
|
362 |
|
|
EPS, rub |
? |
|
-1.43 |
-2.07 |
-2.18 |
-2.63 |
-1.64 |
|
-1.51 |
|
FCF/share, rub |
|
|
-1.33 |
-0.54 |
-2.25 |
-2.93 |
-1.41 |
|
-1.13 |
|
BV/share, rub |
|
|
3.59 |
4.67 |
7.16 |
5.00 |
3.74 |
|
3.08 |
|
|
EBITDA margin, % |
? |
|
-882.1% |
-397.7% |
-378.1% |
-305.9% |
-271.1% |
|
-1 325% |
|
Net margin, % |
? |
|
-914.9% |
-541.8% |
-369.4% |
-264.9% |
-253.3% |
|
-1 325% |
|
FCF yield, % |
? |
|
-6.79% |
-0.59% |
-3.85% |
-29.0% |
-37.6% |
|
-51.1% |
|
ROE, % |
? |
|
-39.9% |
-44.3% |
-30.4% |
-52.7% |
-43.7% |
|
-49.2% |
|
ROA, % |
? |
|
-32.3% |
-27.4% |
-22.4% |
-36.1% |
-31.8% |
|
-36.0% |
|
|
P/E |
? |
|
-13.7 |
-44.0 |
-26.9 |
-3.83 |
-2.29 |
|
-1.45 |
|
P/FCF |
|
|
-14.7 |
-169.6 |
-26.0 |
-3.44 |
-2.66 |
|
-1.96 |
|
P/S |
? |
|
125.0 |
238.3 |
99.3 |
10.1 |
5.79 |
|
19.3 |
|
P/BV |
? |
|
5.45 |
19.5 |
8.17 |
2.02 |
1.00 |
|
0.72 |
|
EV/EBITDA |
? |
|
-12.1 |
-56.8 |
-23.9 |
-2.21 |
-0.91 |
|
-0.34 |
|
Debt/EBITDA |
|
|
2.06 |
3.08 |
2.37 |
1.11 |
1.23 |
|
1.11 |
|
|
R&D/CAPEX, % |
|
|
1 187% |
2 547% |
425.1% |
901.0% |
2 805% |
|
15 191% |
|
|
CAPEX/Revenue, % |
|
|
69.2% |
15.7% |
90.8% |
36.9% |
9.68% |
|
6.05% |
|
| Fate Therapeutics shareholders |
